Arqule shares trip Nasdaq short sale circuit breaker
04 October 2012 Boston
Image: Shutterstock
It has been reported that a plunge in Arqule shares triggered Nasdaq’s short-selling circuit breaker, as countless investors dumped the biotech stock after the company announced that it was discontinuing a key clinical trial.
The Phase 3 MARQUEE Clinical Trial in non-small cell lung cancer, which was undertaken by Arqule and partner Daiichi Sankyo, was carried out in a bid to improve overall survival rates.
According to reports, the independent data monitoring committee of the clinical trial recommended that the study be terminated after it concluded that the study would not meet its primary endpoint.
The Phase 3 MARQUEE Clinical Trial in non-small cell lung cancer, which was undertaken by Arqule and partner Daiichi Sankyo, was carried out in a bid to improve overall survival rates.
According to reports, the independent data monitoring committee of the clinical trial recommended that the study be terminated after it concluded that the study would not meet its primary endpoint.
NO FEE, NO RISK
100% ON RETURNS If you invest in only one securities finance news source this year, make sure it is your free subscription to Â鶹´«Ã½ Finance Times
100% ON RETURNS If you invest in only one securities finance news source this year, make sure it is your free subscription to Â鶹´«Ã½ Finance Times
